Cell and gene Therapy Supply Chain Software Market Size, Share & Trends Analysis Report By Process Component (Sample Collection And Processing Components, Manufacturing Domains, Logistics Components, And Patient Identification And Treatment Follow-Up Components), Type Of Software, Mode Of Deployment, Type Of End-User, And Scale Of Operation, Region And Segment Forecasts, 2025-2034

Report Id: 2520 Pages: 180 Last Updated: 13 June 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Cell & Gene Therapy Supply Chain Software Market -

Cell & Gene Therapy Supply Chain Software Market By Process Component-       

  • Sample Collection and Processing Component
  • Manufacturing Component
  • Logistics Component
  • Patient Identification and Treatment Follow-up Component

Cell and gene Therapy Supply Chain Software Market seg

Cell & Gene Therapy Supply Chain Software Market By Type of Software-

  • Enterprise Manufacturing System (EMS)
  • Laboratory Information Management System (LIMS)
  • Inventory Management System (IMS)
  • Cell Orchestration Platform (COP)
  • Quality Management System (QMS)
  • Logistics Management System (LMS)
  • Patient Management System (PMS)

Cell & Gene Therapy Supply Chain Software Market By Mode of Deployment-    

  • On-premises Deployment
  • Cloud-based Deployment

Cell & Gene Therapy Supply Chain Software Market By Type of End-User-

  • Pharmaceutical Companies
  • Cell Therapy Labs
  • Hospitals / Medical Centers
  • Research Institutes / Biobanks

Cell & Gene Therapy Supply Chain Software Market By Scale of Operation-        

  • Clinical Scale
  • Commercial Scale

By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Cell and Gene Therapy Supply Chain Software Market Snapshot

Chapter 4. Global Cell and Gene Therapy Supply Chain Software Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Process Component Estimates & Trend Analysis

5.1. by Process Component & Market Share, 2024 & 2034

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Process Component:

5.2.1. Sample Collection and Processing Component

5.2.2. Manufacturing Component

5.2.3. Logistics Component

5.2.4. Patient Identification and Treatment Follow-up Component

Chapter 6. Market Segmentation 2: by Type of Software Estimates & Trend Analysis

6.1. by Type of Software & Market Share, 2024 & 2034

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Software:

6.2.1. Enterprise Manufacturing System (EMS)

6.2.2. Laboratory Information Management System (LIMS)

6.2.3. Inventory Management System (IMS)

6.2.4. Cell Orchestration Platform (COP)

6.2.5. Quality Management System (QMS)

6.2.6. Logistics Management System (LMS)

6.2.7. Patient Management System (PMS)

Chapter 7. Market Segmentation 3: by Mode of Deployment Estimates & Trend Analysis

7.1. by Mode of Deployment & Market Share, 2024 & 2034

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Mode of Deployment:

7.2.1. On-premises Deployment

7.2.2. Cloud-based Deployment

Chapter 8. Market Segmentation 4: by Scale of Operation Estimates & Trend Analysis

8.1. by Scale of Operation & Market Share, 2024 & 2034

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Scale of Operation:

8.2.1. Clinical Scale

8.2.2. Commercial Scale

Chapter 9. Market Segmentation 5: by End-User Estimates & Trend Analysis

9.1. by End-User & Market Share, 2024 & 2034

9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-User:

9.2.1. Pharmaceutical Companies

9.2.2. Cell Therapy Labs

9.2.3. Hospitals / Medical Centers

9.2.4. Research Institutes / Biobanks

Chapter 10. Cell and Gene Therapy Supply Chain Software Market Segmentation 6: Regional Estimates & Trend Analysis

10.1. North America

10.1.1. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component,2021-2034

10.1.2. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034

10.1.3. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034

10.1.4. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034

10.1.5. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.1.6. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.2. Europe

10.2.1. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034

10.2.2. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034

10.2.3. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034

10.2.4. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034

10.2.5. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.2.6. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.3. Asia Pacific

10.3.1. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034

10.3.2. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034

10.3.3. Asia-Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034

10.3.4. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034

10.3.5. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.3.6. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.4. Latin America

10.4.1. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034

10.4.2. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034

10.4.3. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034

10.4.4. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034

10.4.5. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.4.6. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.5. Middle East & Africa

10.5.1. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034

10.5.2. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034

10.5.3. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034

10.5.4. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034

10.5.5. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.5.6. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. Azenta Life Sciences

11.2.2. Biocair

11.2.3. BioLife Solutions

11.2.4. CareDx

11.2.5. Cryoport

11.2.6. Lonza

11.2.7. NMDP BioTherapies

11.2.8. TraceLink

11.2.9. TrakCel

11.2.10. Veeva Systems

11.2.11. Emerson

11.2.12. LabVantage Solutions

11.2.13. Marken

11.2.14. MasterControl

11.2.15. QuickSTAT

11.2.16. Siemens

11.2.17. Stafa Cellular Therapy

11.2.18. Steiner

11.2.19. STEMSOFT Software

11.2.20. TECHNIDATA

11.2.21. Thermo Fisher Scientific

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5896
Security Code field cannot be blank!

Frequently Asked Questions

Cell And Gene Therapy Supply Chain Software Market, a rapidly growing sector, Size is valued at USD 269.3 Mn in 2024 and is predicted to reach USD 982

Cell And Gene Therapy Supply Chain Software Market is predicted to develop at a 14.0% CAGR during the forecast period for 2025-2034.

Veeva Systems, Emerson, Cryoport, Marken, MasterControl, Steiner, Siemens, Stafa Cellular Therapy, QuickSTAT, STEMSOFT Software, TECHNIDATA and Thermo

Process Component, Type Of Software, Mode Of Deployment, Type Of End-User, and Scale Of Operation are the key segments of the Cell and gene Therapy Su

North America region is leading the Cell and gene Therapy Supply Chain Software Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying